References
Faries B, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211–2. https://doi.org/10.1056/nejmoa1613210.
Leiter U, Stadler R, Mauch C, et al. Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node. J. Clin. Oncol. 2019;37(32):3000–8. https://doi.org/10.1200/jco.18.02306.
Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757–67. https://doi.org/10.1016/s1470-2045(16)00141-8.
Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–801. https://doi.org/10.1056/nejmoa1802357.
Standage H, Hersh AR, Caughey A, et al. What is the cost-effective treatment of melanoma patients with a positive sentinel node? Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-09137-7.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
Hayley Standage and Dale Han have no financial disclosures and report no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Standage, H., Han, D. ASO Author Reflections: What is the Cost-Effective Treatment of Melanoma Patients with a Positive Sentinel Node?. Ann Surg Oncol 28, 2923–2924 (2021). https://doi.org/10.1245/s10434-020-09168-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-020-09168-0